Regulatory effect of IFN-κ, a novel type I IFN, on cytokine production by cells of the innate immune system

Journal of Immunology

Volumn 169, Issue 9, 2002, Pages 4822-4830

  Nardelli, Bernardetta ^a   Zaritskaya, Liubov ^a   Semenuk, Mark ^a   Cho, Yun Hee ^a   LaFleur, David W ^a   Shah, Devanshi ^a   Ullrich, Stephen ^a   Girolomoni, Giampiero ^a   Albanesi, Cristina ^a   Moore, Paul A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BETA INTERFERON; CYTOKINE; HEPARIN; INTERFERON; INTERLEUKIN 12; KAPPA INTERFERON; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; ATOPIC DERMATITIS; BIOSENSOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MONOCYTE; PRIORITY JOURNAL; PSORIASIS VULGARIS; SIGNAL TRANSDUCTION;

EID: 0036838548     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.9.4822     Document Type: Article

References (47)

1. Roberts, R. M., L. Liu, Q. Guo, D. Leaman, and J. Bixby. 1998. The evolution of type I interferons. J. Interferon Cytokine Res. 18:805.
2. Grander, D., O. Sangfelt, and S. Erickson. 1997. How does interferon exert its cell growth inhibitory effect? Eur. J. Haematol. 59:129.
3. Leaman, D. W. 1998. Mechanism of interferon action. Prog. Mol. Subcell. Biol. 20:101.
4. Belardelli, F., and I. Gresser. 1996. The neglected role of type I interferon in the T cell response: Implications for its clinical use. Immunol. Today 17:369.
5. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189:521.
6. Foster. G. R., and N. B. Finter. 1998. Are all type I human interferons equivalent? J. Viral. Hepat. 5:143.
7. Fish, E., K. Banerjee, and N. Stebbing, 1983. Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem. Biophys. Res. Commum. 112:537.
8. Rankel, L., L. Pfeffer, M. Lewerenz, D. Monneron, C. H. Yang, A. Murti, S. Pellegrini, S. Goelz, G. Uze, and K. Mogensen. 1998. Differences in activity between α and β type I interferons explored by mutational analysis. J. Biol. Chem. 273:8003.
9. Hibbert, L., and G. R. Foster. 1999, Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J. Interferon Cytokine Res. 19:309.
10. Pestka, S. 1997. The human interferon-α species and hybrid proteins. Semin. Oncol. 24(Suppl. 9):4.
11. Foster, G., O. Rodrigues, F. Ghouze, E. Schulte-Frohlinde, D. Testa, M. J. Liao, G. R. Stark, L. Leadbeater, and H. C. Thomas. 1996. Different relative activities of human cell derived interferon-α subtypes: IFN-α8 has very high antiviral potency. J. Interferon Cytokine Res. 16:1027.
12. Rosenblum, M. G., W. K. Yung, P. J. Kelleher, F. Ruzicka, P. A. Steck, and E. C. Borden. 1990. Growth inhibitory effects of interferon-β but not interferon-α on human glioma cells: Correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. J. Interferon Res. 10:141.
13. The IFNβ-1b Multiple Sclerosis Study Group. 1993. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. Neurology 43:655.
14. Jacobs, L. D., D. L. Cookfair, R. A. Rudick, R. M. Herdon, J. R. Richert, A. M. Salazar, J. S. Fischer, D. E. Goodkin, C. V. Granger, J. H. Simon, et al. 1996. Intramuscular IFN β-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:285.
15. La Fleur, D. W., B. Nardelli, T. Tsareva, D. Mather, P. Feng, M. Semenuk, K. Taylor, M. Buergin, D. Chincilla, V. Roschke, et al. 2001. Interferon-K, a novel type I IFN expressed in human keratinocytes. J. Biol. Chem. 276:39765.
16. Myszka, D. G. 1999. Improving biosensor analysis. J. Mol. Recognit. 12:279.
17. Pfeffer, L. M., C. A. Dinarello, R. B. Herberman, B. R. Williams, E. C. Borden, R. Bordens, M. R. Walker, T. L. Nagabhushan, P.P. Trotta, and S. Pestka. 1998. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58:2489.
18. Rudick, R. A., R. M. Ransohoff, J. C. Lee, R. Peppler, M. Yu, P. M. Mathisen, and V. K. Tuohy. 1998. In vivo effects of interferon β-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50:1294.
19. Dzionek, A., A. Fuchs, P. Schmidt, S. Cremer, M. Zysk, S. Miltenyi, D. W. Buck, and J. Schmitz. 2000. BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J. lmmunol. 165:6037.
20. Hayes, M. P., J. Wang, and M. A. Norcross. 1995. Regulation of IL-12 expression in human monocytes: Selective priming by IFN-γ of LPS-inducible p35 and p40 genes. Blood 86:646.
21. Ma, X., J. Sun, E. Papasavvas, H. Riemann, S. Roberton, J. Marshall, R. T. Bailer, A. Moore, R. P. Donnelly, G. Trinchieri, and L. J. Montaner. 2000. Inhibition of IL-12 production in human monocyte-derived macrophages by TNF. J. Immunol. 165:1722.
22. Chensue, S. W., K. S. Warmington, J. H. Ruth, P. S. Sanghi, P. Lincoln, and S. L. Kunkel. 1996. Role of monocyte chemoattractant protein-I (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation. J. Immunol. 157:4602.
23. McRae, B. J., B. A. Beilfuss, and G. A. van Seventer. 2000. IFN-β differentially regulates CD40-induced cytokine secretion by human dendritic cells. J. Immunol. 164:23.
24. Dzionek, A., Y. Sohma, J. Nagafune, M. Cella, M. Colonna, F. Facchetti, G. Gunther, I. Johnson, A. Lanzavecchia, T. Nagasaka, et al. 2001. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J. Exp. Med. 194:1823.
25. Lortat-Jacob, H., and J. A. Grimaud. 1992. Binding of IFN-γ to heparan sulfate is restricted to the heparin-like domains and involves carboxylic- but not N-sulfated groups. Biochim. Biophys. Acta 1117:126.
26. Patankar, M. S., S. Oehninger, T. Barnett, R. L. Williams, and G. F. Clark. 1993. A revised structure for fucoidan may explain some of its biological activities. J. Biol. Chem. 268:21770.
27. Pestka, S. 1997. The interferon receptors. Semin. Oncol. 24(Suppl. 9):18.
28. Mogensen, K. E., M. Lewerenz, J. Reboul, G. Lutfalla, and G. Uze. 1999. The type I interferon receptor: Structure, function and evolution of a family business. J. Interferon Cytokine Res. 19:1069.
29. Hu, R., J. Bekisz, M. Hayes, S. Audet, J. Beeler, E. Petricoin, and K. Zoon. 1999. Divergence of binding, signaling and biological responses to recombinant human hybrid IFN. J. Immunol. 163:854.
30. Petricoin, E. F., S. Ito, B. L. Williams, S. Audet, L. F. Stancato, A. Gamero, K. Clouse, P. Grimley, A. Weiss, J. Beeler, et al. 1997. Antiproliferative action of interferon-a requires components of T-cell receptor signaling. Nature 390:629.
31. L subunit of the type I interferon (IFN) receptor determines signaling specificity for IFN-α2 and IFN-β. J. Biol. Chem. 273:3144.
32. Lewerenz, M., K. E. Mogensen, and G. Uze. 1998. Shared receptor components but distinct complexes for α and β interferons. J. Mol. Biol. 282:585.
33. Rogge, L., L. Barberis-Maino, N. Passini, D. H. Presky, U. Gubler, and F. Sinigaglia. 1997. Selective expression of an interleukin-12 receptor component by human T helper I cells. J. Exp. Med. 185:825.
34. Cousens, L. P., J. S. Orange, H. C. Su, and C. A. Biron. 1997. Interferon-α/β inhibition of interleukin-12 and interferon-γ production in vitro and endogenously during viral infection. Proc. Natl. Acad. Sci. USA 94:634.
35. Wang, X., M. Chen, K. P. Wandinger, G. Williams, and S. Dhib-Jalbut. 2000. IFN-β-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: Relevance to IFN-β-1b therapeutic effects in multiple sclerosis. J. Immunol. 165:548.
36. Van Boxel-Dezaire, A. H., S. C. Hoff, B. W. van Oosten, C. L. Verweij, A. M. Drager, H. J. Ader, J. C. van Houwelinger, F. Barkhof, C. H. Polman, and L. Nagelkerken. 1999. Decreased IL-10 and increased IL-12 p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45:695.
37. Howard, M., T. Muchamuel, S. Andrade, and S. Menon. 1993. IL-10 protects mice from lethal endotoxemia. J. Exp. Med. 177:1205.
38. Wysocka, M., M. Kubin, L. Q. Vieria, L. Ozmen, G. Garotta, P. Scott, and G. Trinchieri. 1995. IL-12 is required for IFN-γ production and lethality in LPS-induced shock in mice. Eur. J. Immunol. 25:672.
39. McCaffrey, T. A., D. J. Falcone, and B. Du. 1992. Transforming growth factor-βi is a heparin binding protein: Identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-β1. J. Cell Physiol. 152-430.
40. Spillmann, D., D. Witt, and U. Lindahl. 1998. Defining the IL-8-binding domain of heparan sulfate. J. Biol. Chem. 273:15487.
41. Hasan, M., S. Najjam, M. Y. Gordon, R. V. Gibbs, and C. C. Rider. 1999. IL-12 is a heparin-binding cytokine. J. Immunol. 162:1064.
42. Najjam, S., B. Mulloy, J. Theze, M. Gordon, R. Gibbs, and C. C. Rider. 1998. Further characterization of the binding of human recombinant IL-2 to heparin and identification of putative binding sites. Glycobiology 8:509.
43. Salek-Ardakani, S., J. R. Arrand, D. Shaw, and M. Mackett. 2000. Heparin and heparan sulfate bind IL-10 and modulate its activity. Blood 96:1879.
44. Hileman, R. E., J. R. Fromm, J. M. Weiler, and R. J. Linhardt. 1998. Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins. BioEssays 20:156.
45. Koopman, W., C. Ediriwickrema, and M. S. Krangel. 1999. Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1β. J. Immunol. 163:2120.
46. Gessani, S., F. Belardelli, A. Pecorelli, P. Puddu, and C. Baglioni. 1989. Bacterial lipopolysaccharide and γ interferon induce transcription of β interferon mRNA and interferon secretion in murine macrophages. J. Virol. 63:2785.
47. Hayes, M. P., J. C. Enterline, T. L. Gerrard, and K. C. Zoon. 1991. Regulation of interferon production by human monocytes: Requirements for priming for lipopolysaccharide-induced production. J. Leukocyte Biol. 50:176.